secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001764013-24-000107
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports Q4 net loss $75.3M, cash $635M; plans 4-5 registrational IMVT-1402 studies by 2025
--------------------------------------------------------------------------------

- Net loss $75.3M ($0.52/sh) for Q4 FY2024 vs $59.4M ($0.46/sh) YoY; FY net loss $259.3M ($1.88/sh).
- Cash and equivalents $635M as of March 31, 2024; R&D expenses $66.1M in Q4.
- Following FDA Type B meeting, on track to initiate 4-5 registrational studies for IMVT-1402 by March 31, 2025.
- Batoclimab MG topline results expected by end of fiscal 2025; CIDP trial extended ~2 quarters before unblinding.
- Composition-of-matter patent for IMVT-1402 issued with term through June 2043.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000107/0001764013-24-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000107/imvt-20240529.htm
  HTML page:      https://secwatch.observer/filing/0001764013-24-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer